Condensed Consolidated Statements of Earnings (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended			9 Months Ended
	Mar. 31, 2013		Mar. 31, 2012	Mar. 31, 2013		Mar. 31, 2012
Income Statement [Abstract]
Revenue	$ 24,552		$ 26,918	$ 75,673		$ 80,788
Cost of products sold	23,261		25,711	72,000		77,383
Gross margin	1,291		1,207	3,673		3,405
Operating expenses:
Distribution, selling, general and administrative expenses	712		683	2,099		1,966
Restructuring and employee severance	33	[1]	7	39	[1]	12
Acquisition-related costs	53		(27)	106		23
Impairments and loss on disposal of assets	21		17	27		19
Litigation (recoveries)/charges, net	(3)		0	(37)		(3)
Operating earnings	475		527	1,439		1,388
Other income, net	(6)		(7)	(17)		(3)
Interest expense, net	34		24	87		70
Earnings before income taxes and discontinued operations	447		510	1,369		1,321
Provision for income taxes	101		178	448		487
Earnings from continuing operations	346		332	921		834
Earnings/(loss) from discontinued operations, net of tax	(1)		1	(1)		(2)
Net earnings	$ 345		$ 333	$ 920		$ 832
Basic earnings/(loss) per Common Share:
Continuing operations	$ 1.01		$ 0.96	$ 2.70		$ 2.42
Discontinued operations	$ 0.00		$ 0.00	$ 0.00		$ (0.01)
Net basic earnings per Common Share	$ 1.01		$ 0.96	$ 2.70		$ 2.41
Diluted earnings/(loss) per Common Share:
Continuing operations	$ 1.00		$ 0.95	$ 2.68		$ 2.39
Discontinued operations	$ 0.00		$ 0.00	$ (0.01)		$ (0.01)
Net diluted earnings per Common Share	$ 1.00		$ 0.95	$ 2.67		$ 2.38
Weighted-average number of Common Shares outstanding:
Weighted-average Common Shares-basic	341		345	341		345
Weighted-average Common Shares-diluted	345		349	344		349
Cash dividends declared per Common Share	$ 0.275		$ 0.215	$ 0.7875		$ 0.645

[1] Includes $25 million of employee-related costs and $4 million of facility exit and other costs related to the restructuring plan within our Medical segment.